These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16293337)

  • 21. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.
    Fujita N; Kaito M; Kai M; Sugimoto R; Tanaka H; Horiike S; Konishi M; Iwasa M; Watanabe S; Adachi Y
    J Viral Hepat; 2006 Jul; 13(7):441-8. PubMed ID: 16792537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.
    Chainuvati S; Khalid SK; Kancir S; Shea M; Edwards J; Sernyak M; Wongcharatrawee S; Garcia-Tsao G
    J Viral Hepat; 2006 Apr; 13(4):235-41. PubMed ID: 16611189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of the efficacy of antiviral therapy for hepatitis C virus infection by an ultrasensitive RT-PCR assay.
    Kinai E; Hanabusa H; Kato S
    J Med Virol; 2007 Aug; 79(8):1113-9. PubMed ID: 17596840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C viremia persistently suppressed by HAART.
    Ranieri R; Santambrogio C; Veronelli A; Pontiroli AE
    Clin Infect Dis; 2003 Apr; 36(8):1086-7. PubMed ID: 12684926
    [No Abstract]   [Full Text] [Related]  

  • 25. Low-level HCV viraemia after initial response during antiviral therapy: transcription-mediated amplification predicts treatment failure.
    Gelderblom HC; Reesink HW; Beld MG; Weegink CJ; Jansen PL; Dijkgraaf MG; Zaaijer HL
    Antivir Ther; 2007; 12(3):423-7. PubMed ID: 17591033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.
    Kwong AD; Najera I; Bechtel J; Bowden S; Fitzgibbon J; Harrington P; Kempf D; Kieffer TL; Koletzki D; Kukolj G; Lim S; Pilot-Matias T; Lin K; Mani N; Mo H; O'Rear J; Otto M; Parkin N; Pawlotsky JM; Petropoulos C; Picchio G; Ralston R; Reeves JD; Schooley RT; Seiwert S; Standring D; Stuyver L; Sullivan J; Miller V; ; ; ;
    Gastroenterology; 2011 Mar; 140(3):755-60. PubMed ID: 21255574
    [No Abstract]   [Full Text] [Related]  

  • 27. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Takagi M; Nakano S; Arakawa T; Fujimori M
    J Med Virol; 2009 Aug; 81(8):1354-62. PubMed ID: 19551828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
    Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
    J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment predictors of a sustained virologic response in hepatitis B and C.
    Kau A; Vermehren J; Sarrazin C
    J Hepatol; 2008 Oct; 49(4):634-51. PubMed ID: 18715665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy.
    Mosley JW; Operskalski EA; Tobler LH; Buskell ZJ; Andrews WW; Phelps B; Dockter J; Giachetti C; Seeff LB; Busch MP;
    J Viral Hepat; 2008 Feb; 15(2):120-8. PubMed ID: 18184195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection.
    Höroldt B; Haydon G; O'Donnell K; Dudley T; Nightingale P; Mutimer D
    Liver Int; 2006 Aug; 26(6):650-9. PubMed ID: 16842320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon-ribavirin therapy.
    Ogata K; Kashiwagi T; Iwahashi J; Hara K; Honda H; Ide T; Kumashiro R; Kohara M; Sata M; Watanabe H; Hamada N
    Arch Virol; 2008; 153(8):1575-9. PubMed ID: 18592133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma.
    De Mitri MS; Cassini R; Morsica G; Bagaglio S; Andreone P; Loggi E; Muratori P; Bernardi M
    J Viral Hepat; 2006 Sep; 13(9):574-81. PubMed ID: 16907843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viral kinetics in hepatitis C.
    Lutchman G; Hoofnagle JH
    Hepatology; 2003 Jun; 37(6):1257-9. PubMed ID: 12774002
    [No Abstract]   [Full Text] [Related]  

  • 37. EASL Recommendations on Treatment of Hepatitis C 2016.
    European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu
    J Hepatol; 2017 Jan; 66(1):153-194. PubMed ID: 27667367
    [No Abstract]   [Full Text] [Related]  

  • 38. Practical insights into enhanced management of patients with HCV infection with direct antiviral agents.
    Colombo M; Zeuzem S
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S313. PubMed ID: 24091108
    [No Abstract]   [Full Text] [Related]  

  • 39. The "gold-standard," accuracy, and the current concepts: hepatitis C virus genotype and viremia.
    Ohno T; Lau JY
    Hepatology; 1996 Nov; 24(5):1312-5. PubMed ID: 8903414
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacogenomics of hepatitis C and decision analysis: a glimpse into the future.
    Wong JB
    Hepatology; 2002 Jul; 36(1):252-4. PubMed ID: 12085373
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.